Anaveon is a clinical-stage biopharmaceutical company focused on developing innovative immunotherapies that leverage the power of engineered cytokines to enhance immune responses against cancer. Their lead compound, ANV419, is a selective interleukin-2 (IL-2) agonist designed to target cancer by preferentially stimulating CD8 T cells and natural killer (NK) cells while minimizing the expansion of regulatory T cells, which can inhibit anti-tumor activity. This unique fusion protein combines IL-2 with an anti-IL-2 monoclonal antibody, allowing it to signal through the IL-2 receptor beta/gamma pathway, thus improving safety and efficacy compared to traditional IL-2 therapies. Anaveon is currently conducting Phase I/II clinical trials to evaluate the safety and clinical activity of ANV419 in patients with advanced solid tumors.

In addition to ANV419, Anaveon is developing other compounds such as ANV600 and ANV700, which aim to further enhance anti-tumor immune responses. ANV600 is a bispecific molecule that targets IL-2 to tumor-infiltrating lymphocytes (TILs) to overcome TIL exhaustion, thereby increasing their tumor-killing potential. Meanwhile, ANV700 is designed to selectively direct IL-21 to tumor-reactive T cells, enhancing their cytotoxic function while mitigating potential negative effects on the immune response. These innovative approaches position Anaveon at the forefront of immuno-oncology, with the potential to provide significant therapeutic benefits for patients with various cancers.

Switzerland

A start up based in Switzerland that develops biologics to modulate the functions of cytokines and provide substantial therapeutic benefits to cancer patients.

Anaveon

Company Details